...
首页> 外文期刊>Applied Microbiology and Biotechnology >Culturable rare Actinomycetes: Diversity, isolation and marine natural product discovery
【24h】

Culturable rare Actinomycetes: Diversity, isolation and marine natural product discovery

机译:可培养的稀有放线菌:多样性,分离和海洋天然产物的发现

获取原文
获取原文并翻译 | 示例
           

摘要

Rare Actinomycetes from underexplored marine environments are targeted in drug discovery studies due to the Actinomycetes' potentially huge resource of structurally diverse natural products with unusual biological activity. Of all marine bacteria, 10 % are Actinomycetes, which have proven an outstanding and fascinating resource for new and potent bioactive molecules. Past and present efforts in the isolation of rare Actinomycetes from underexplored diverse natural habitats have resulted in the isolation of about 220 rare Actinomycete genera of which more than 50 taxa have been reported to be the producers of 2,500 bioactive compounds. That amount represents greater than 25 % of the total Actinomycetes metabolites, demonstrating that selective isolation methods are being developed and extensively applied. Due to the high rediscovery rate of known compounds from Actinomycetes, a renewed interest in the development of new antimicrobial agents from rare and novel Actinomycetes is urgently required to combat the increasing number of multidrug-resistant human pathogens. To facilitate that discovery, this review updates all selective isolation media including pretreatment and enrichment methods for the isolation of marine rare Actinomycetes. In addition, this review demonstrates that discovering new compounds with novel scaffolds can be increased by intensive efforts in isolating and screening rare marine genera of Actinomycetes. Between 2007 and mid-2013, 80 new rare Actinomycete species were reported from marine habitats. They belong to 23 rare families, of which three are novel, and 20 novel genera. Of them, the family Micromonosporaceae is dominant as a producer of promising chemical diversity.
机译:由于放线菌具有结构异常的生物活性的结构多样的天然产物的潜在巨大资源,因此来自未开发海洋环境的稀有放线菌被用于药物发现研究。在所有海洋细菌中,放线菌占10%,事实证明,放线菌是新的有效生物活性分子的绝佳资源。从未开发的各种自然栖息地中分离稀有放线菌的过去和现在的努力已导致分离出约220个稀有放线菌属,据报道其中50个分类单元是2,500种生物活性化合物的生产者。该量占放线菌代谢物总量的25%以上,这表明选择性分离方法正在开发和广泛应用。由于来自放线菌的已知化合物的高再发现率,迫切需要开发来自稀有和新颖的放线菌的新抗菌剂的新兴趣,以对抗越来越多的耐多种药物的人类病原体。为了促进这一发现,本综述更新了所有选择性分离介质,包括用于分离海洋稀有放线菌的预处理和富集方法。此外,这项审查表明,通过分离和筛选放线菌的稀有海洋属的深入努力,可以增加发现具有新颖支架的新化合物的可能性。从2007年到2013年中,据报道海洋生境中有80种新的放线菌物种。它们属于23个稀有家族,其中3个是新奇的,20个新属。其中,Micromonosporaceae家族作为有前途的化学多样性的生产者而占主导地位。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号